Precision medicine approach identifies new therapeutic candidates for medulloblastoma

Written by Sharon Salt, Senior Editor

A group of researchers has demonstrated that precision medicine – specifically personalized drug screens – can be used to identify new therapeutic candidates for medulloblastoma. This approach uses tumor cells obtained from a biopsy to measure the effectiveness of therapeutics and can be performed in just a few days. “Our findings show that personalized drug screens can help us move away from a one-size-fits-all approach to treating medulloblastoma patients. We have shown that we can identify therapies that cannot be predicted using other methods, and that the results can be used in clinical decision-making to improve outcomes for patients,” explained...

To view this content, please register now for access

It's completely free